BioCatalystWatch
AKTSWorkspace / AKTS / OverviewCompany library
Aktis Oncology, Inc. logo

Aktis Oncology, Inc.

Aktis Oncology, Inc. (AKTS)

Website

Price
Market cap
Next catalystExpected Q1 2027AKY-1189 — NECTINIUM-2 · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

AKY-2519

B7-H3 (CD276)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved
Upcoming / outlook

AKY-2519

B7-H3 (CD276)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

AKY-2519

B7-H3 (CD276)

PreINDP1P2P3FilingApproved
AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved
AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved
AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved
AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved
AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved
AKY-1189

Nectin-4

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

AKTS PR & News

PR & News

AKTS SEC archive